HIGHLIGHTS
- who: TOR signaling pathway regulator et al. from the China Pharmaceutical University, China have published the paper: Research progress on the relationship between the TOR signaling pathway regulator, epigenetics, and tumor development, in the Journal: (JOURNAL)
- what: Because it inhibits the activity of a wide variety of well-known oncogenes, such as MYC, BCL-2, ERK, and AKT, the PP2A holoenzyme is considered a tumor suppressor (Lin et_al, 2006; Ruvolo et_al, 2011) .
SUMMARY
Ataxia telangiectasia mutated (ATM) and ATM and Rad3-dependent phosphorylation events (ATR) are suppressed by TIPRL interaction with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.